GSK-4112

GSK-4112 is an experimental drug that was developed by GlaxoSmithKline as an agonist of Rev-ErbAα.^[1] It is used for studying regulation of the circadian rhythm and its influence on diverse processes such as adipogenesis,^[2][3] regulation of bone density,^[4] and inflammation.^[5][6][7][8]

GSK-4112

Identifiers
IUPAC name tert-butyl 2-[(4-chlorophenyl)methyl-[(5-nitrothiophen-2-yl)methyl]amino]acetate
CAS Number	1216744-19-2
PubChem CID	50905018
ChemSpider	24606038
ChEMBL	ChEMBL1961795
CompTox Dashboard (EPA)	DTXSID701336675
Chemical and physical data
Formula	C18H21ClN2O4S
Molar mass	396.89 g·mol−1
3D model (JSmol)	Interactive image
SMILES CC(C)(C)OC(=O)CN(CC1=CC=C(C=C1)Cl)CC2=CC=C(S2)[N+](=O)[O-]
InChI InChI=1S/C18H21ClN2O4S/c1-18(2,3)25-17(22)12-20(10-13-4-6-14(19)7-5-13)11-15-8-9-16(26-15)21(23)24/h4-9H,10-12H2,1-3H3 Key:WYSLOKHVFKLWOU-UHFFFAOYSA-N

See also

• SR8278
• SR9009
• SR9011